Novel AI-powered platform aims to help ALS patients to communicate

Novel AI-powered platform aims to help ALS patients to communicate

Researchers have unveiled a new AI-powered avatar platform — one making use of artificial intelligence (AI) technology — that aims to help people with amyotrophic lateral sclerosis (ALS) to communicate, even when the neurodegenerative disease progresses to the point that speaking and moving become difficult or impossible. The platform…

The strange calculations we make while living with ALS

One of my favorite Christmas gifts this year was balsamic vinegar — two bottles, actually — that my husband, Todd, gave me. Todd has ALS and is paralyzed, so he spends time watching YouTube videos about various subjects. A couple months ago, he came across a video that explained…

Coya aligns with FDA on plans for developing COYA 302 for ALS

After two meetings with the U.S. Food and Drug Administration (FDA), Coya Therapeutics says it’s received constructive feedback — and has reached an alignment with the agency regarding development plans for COYA 302, its therapy candidate for people with amyotrophic lateral sclerosis (ALS). The company held the two…

Arbor, 4DMT to develop novel gene therapies for ALS, other diseases

Arbor Biotechnologies and 4DMT — two U.S. companies working in next-generation genetic medicines — have established a strategic partnership to develop and commercialize novel gene therapies for neurological diseases, including amyotrophic lateral sclerosis (ALS). The agreement includes the codevelopment of up to six product candidates for diseases…

NurOwn and its exosomes given patents in Europe, Australia, Israel

BrainStorm Cell Therapeutics has received patents in Europe, Australia, and Israel covering the use of investigational NurOwn and NurOwn exosomes in treating amyotrophic lateral sclerosis (ALS) and other neurological disorders. The European patent specifically covers the use of an isolated population of mesenchymal stem cells —…

Juvenile-onset ALS linked to new SPTLC2 mutation: Study

A previously unknown mutation in the SPTLC2 gene was identified in two patients who developed juvenile-onset amyotrophic lateral sclerosis (ALS), a study reports. The mutation significantly increased the production of certain types of fat-like molecules called sphingolipids, resulting in early-onset muscle weakness, progressive motor impairment, and involuntary tongue movements.

Researchers develop algorithm to predict ALS survival

Researchers have developed an algorithm to generate personalized survival predictions for people with amyotrophic lateral sclerosis (ALS) based on clinical and MRI features. The scientists believe the algorithm could help patients and doctors make better treatment and care plans. “The disease progression varies greatly for ALS patients, so it…